cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Anavex Life Sciences Corp
19 own
31 watching
Current Price
$10.87
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
488.19M
52-Week High
52-Week High
12.48000
52-Week Low
52-Week Low
3.25
Average Volume
Average Volume
2.88M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization488.19M
icon52-Week High12.48000
icon52-Week Low3.25
iconAverage Volume2.88M
iconDividend Yield--
iconP/E Ratio--
What does the Anavex Life Sciences Corp do?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Read More
How much money does Anavex Life Sciences Corp make?
News & Events about Anavex Life Sciences Corp.
TipRanks Financial Blog
1 year ago
In a report released today, Caroline Palomeque from Berenberg Bank reiterated a Buy rating on Anavex Life Sciences (AVXL Research Report), with a... In a report released today, Caroline Palomeque from Berenberg Bank reiterated a Buy rating on Anavex Life Sciences (AVXL &#8211...
Globe Newswire
1 year ago
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, ...
Zolmax
1 year ago
Anavex Life Sciences (NASDAQ:AVXL Get Rating) and Icosavax (NASDAQ:ICVX Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst ...
Benzinga
1 year ago
read more...
Benzinga
2years ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Anavex Life Sciences Corp share price today?
plus_minus_icon
Can Indians buy Anavex Life Sciences Corp shares?
plus_minus_icon
How can I buy Anavex Life Sciences Corp shares from India?
plus_minus_icon
Can Fractional shares of Anavex Life Sciences Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Anavex Life Sciences Corp stocks?
plus_minus_icon
What is today’s traded volume of Anavex Life Sciences Corp?
plus_minus_icon
What is today’s market capitalisation of Anavex Life Sciences Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Anavex Life Sciences Corp?
plus_minus_icon
What percentage is Anavex Life Sciences Corp down from its 52-Week High?
plus_minus_icon
What percentage is Anavex Life Sciences Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$10.87
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$8.86
$-0.08 (-0.89 %)
Vericel Corporation
Vericel Corporation
$57.31
$0.27 (0.47 %)
Mesoblast
Mesoblast
$17.02
$-0.21 (-1.22 %)
Gevo Inc
Gevo Inc
$1.51
$-0.01 (-0.66 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$8.86
$-0.08 (-0.89 %)
Vericel Corporation
Vericel Corporation
$57.31
$0.27 (0.47 %)
Mesoblast
Mesoblast
$17.02
$-0.21 (-1.22 %)
Gevo Inc
Gevo Inc
$1.51
$-0.01 (-0.66 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00